The impact of exposure to antidepressant medications during pregnancy on neonatal outcomes: a review of retrospective database cohort studies

Cooper WO, Willy ME, Pont SJ, Ray WA. Increasing use of antidepressants in pregnancy. American journal of obstetrics and gynecology. 2007;196(6):544.e541–545. Koren G, Nordeng H (2012) Antidepressant use during pregnancy: the benefit-risk ratio. Am J Obstet Gynecol 207(3):157–163 Hanley GE, Oberlander TF (2014) The effect of perinatal exposures on the infant: antidepressants and depression. Best Pract Res Clin Obstet Gynaecol 28(1):37–48 Gavin NI, Gaynes BN, Lohr KN, Meltzer-Brody S, Gartlehner G, Swinson T (2005) Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol 106(5 Pt 1):1071–1083 The American College of Obstetricians and Gynecologists Committee Opinion no. 630. Screening for perinatal depression. Obstetrics and gynecology. 2015;125(5):1268–1271. Suri R, Lin AS, Cohen LS, Altshuler LL (2014) Acute and long-term behavioral outcome of infants and children exposed in utero to either maternal depression or antidepressants: a review of the literature. J Clin Psychiatry 75(10):e1142–e1152 Kelly RH, Danielsen BH, Golding JM, Anders TF, Gilbert WM, Zatzick DF. Adequacy of prenatal care among women with psychiatric diagnoses giving birth in California in 1994 and 1995. Psychiatric services (Washington, DC). 1999;50(12):1584–1590. Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR (2004) Depression during pregnancy : overview of clinical factors. Clinical drug investigation 24(3):157–179 Horrigan TJ, Schroeder AV, Schaffer RM (2000) The triad of substance abuse, violence, and depression are interrelated in pregnancy. J Subst Abus Treat 18(1):55–58 Broudy C, Payne JG (2013) A dangerous bias. Hum Reprod 28(4):1148–1149 Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM (2007) Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 356(26):2684–2692 Andrade SE, Raebel MA, Brown J, et al. Use of antidepressant medications during pregnancy: a multisite study. American journal of obstetrics and gynecology. 2008;198(2):194.e191–195. Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernandez-Diaz S. Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008. American journal of obstetrics and gynecology. 2011;205(1):51.e51–58. Huybrechts KF, Palmsten K, Avorn J et al (2014) Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med 370(25):2397–2407 Ramos E, Oraichi D, Rey E, Blais L, Berard A (2007) Prevalence and predictors of antidepressant use in a cohort of pregnant women. BJOG : an international journal of obstetrics and gynaecology 114(9):1055–1064 McDonagh MS, Matthews A, Phillipi C et al (2014) Antidepressant treatment of depression during pregnancy and the postpartum period. Evidence Report/Technology Assessment AHRQ 216 Stockmann C, Sherwin CM, Koren G et al (2014) Characteristics and publication patterns of obstetric studies registered in ClinicalTrials.gov. J Clin Pharmacol 54(4):432–437 Zajicek A, Giacoia GP (2007) Obstetric clinical pharmacology: coming of age. Clin Pharmacol Ther 81(4):481–482 Simon GE, Cunningham ML, Davis RL (2002) Outcomes of prenatal antidepressant exposure. Am J Psychiatry 159(12):2055–2061 Malm H, Klaukka T, Neuvonen PJ (2005) Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 106(6):1289–1296 Hayes RM, Wu P, Shelton RC, et al. Maternal antidepressant use and adverse outcomes: a cohort study of 228,876 pregnancies. American journal of obstetrics and gynecology. 2012;207(1):49.e41–49. Kallen B (2012) The problem of confounding in studies of the effect of maternal drug use on pregnancy outcome. Obstet Gynecol Int 2012:148616 Wogelius P, Norgaard M, Gislum M, et al. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology (Cambridge, Mass). 2006;17(6):701–704. Andrews EB, Tennis P (2007) Promise and pitfalls of administrative data in evaluating pregnancy outcomes. Pharmacoepidemiol Drug Saf 16(11):1181–1183 Wen SW, Yang Q, Garner P et al (2006) Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 194(4):961–966 Kallen B, Nilsson E, Olausson PO (2011) Antidepressant use during pregnancy: comparison of data obtained from a prescription register and from antenatal care records. Eur J Clin Pharmacol 67(8):839–845 Colvin L, Slack-Smith L, Stanley FJ, Bower C (2011) Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Birth defects research Part A, Clinical and molecular teratology. 91(3):142–152 Colvin L, Slack-Smith L, Stanley FJ, Bower C (2012) Early morbidity and mortality following in utero exposure to selective serotonin reuptake inhibitors: a population-based study in Western Australia. CNS drugs 26(7):e1–14 Grzeskowiak LE, Gilbert AL, Morrison JL (2012) Neonatal outcomes after late-gestation exposure to selective serotonin reuptake inhibitors. J Clin Psychopharmacol 32(5):615–621 Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C (2006) Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 63(8):898–906 Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C (2008) Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. The British journal of psychiatry : the journal of mental science. 192(5):338–343 Oberlander TF, Warburton W, Misri S, Riggs W, Aghajanian J, Hertzman C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth defects research Part B, Developmental and reproductive toxicology 2008;83(1):68–76. Warburton W, Hertzman C, Oberlander TF (2010) A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. Acta Psychiatr Scand 121(6):471–479 Einarson A, Choi J, Einarson TR, Koren G (2010) Adverse effects of antidepressant use in pregnancy: an evaluation of fetal growth and preterm birth. Depression and anxiety 27(1):35–38 Berard A, Zhao JP, Sheehy O. Sertraline use during pregnancy and the risk of major malformations. American journal of obstetrics and gynecology. 2015;212(6):795.e791–795.e712. Margulis AV, Abou-Ali A, Strazzeri MM et al (2013) Use of selective serotonin reuptake inhibitors in pregnancy and cardiac malformations: a propensity-score matched cohort in CPRD. Pharmacoepidemiol Drug Saf 22(9):942–951 Sutter-Dallay AL, Bales M, Pambrun E, Glangeaud-Freudenthal NM, Wisner KL, Verdoux H (2015) Impact of prenatal exposure to psychotropic drugs on neonatal outcome in infants of mothers with serious psychiatric illnesses. J Clin Psychiatry. 76(7):967–973 Ericson A, Kallen B, Wiholm B (1999) Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 55(7):503–508 Kallen BA, Otterblad OP (2007) Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth defects research Part A, Clinical and molecular teratology 79(4):301–308 Kallen B, Olausson PO (2008) Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 17(8):801–806 Lennestal R, Kallen B (2007) Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol 27(6):607–613 Reis M, Kallen B (2010) Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 40(10):1723–1733 Jimenez-Solem E, Andersen JT, Petersen M et al (2013) SSRI use during pregnancy and risk of stillbirth and neonatal mortality. Am J Psychiatry 170(3):299–304 Jensen HM, Gron R, Lidegaard O, Pedersen LH, Andersen PK, Kessing LV (2013) Maternal depression, antidepressant use in pregnancy and Apgar scores in infants. The British journal of psychiatry : the journal of mental science 202(5):347–351 Jensen HM, Gron R, Lidegaard O, Pedersen LH, Andersen PK, Kessing LV (2013) The effects of maternal depression and use of antidepressants during pregnancy on risk of a child small for gestational age. Psychopharmacology 228(2):199–205 Jimenez-Solem E, Andersen JT, Petersen M, et al. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ open. 2012;2(3). Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ (Clinical research ed). 2009;339:b3569. Nordeng H, van Gelder MM, Spigset O, Koren G, Einarson A, Eberhard-Gran M (2012) Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian Mother and Child Cohort Study. J Clin Psychopharmacol 32(2):186–194 Furu K, Kieler H, Haglund B, et al. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. BMJ (Clinical research ed). 2015;350:h1798. Kieler H, Artama M, Engeland A, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ (Clinical research ed). 2012;344:d8012. Stephansson O, Kieler H, Haglund B et al (2013) Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. JAMA 309(1):48–54 Davis RL, Rubanowice D, McPhillips H et al (2007) Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf 16(10):1086–1094 Cole JA, Ephross SA, Cosmatos IS, Walker AM (2007) Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 16(10):1075–1085 Cole JA, Modell JG, Haight BR, Cosmatos IS, Stoler JM, Walker AM (2007) Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 16(5):474–484 Huybrechts KF, Bateman BT, Palmsten K et al (2015) Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA 313(21):2142–2151 Andrade SE, McPhillips H, Loren D et al (2009) Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 18(3):246–252 Udechuku A, Nguyen T, Hill R, Szego K (2010) Antidepressants in pregnancy: a systematic review. The Australian and New Zealand journal of psychiatry 44(11):978–996 Colvin L, Slack-Smith L, Stanley FJ, Bower C (2013) Are women with major depression in pregnancy identifiable in population health data? BMC pregnancy and childbirth 13:63 Petersen I, Gilbert RE, Evans SJ, Man SL, Nazareth I (2011) Pregnancy as a major determinant for discontinuation of antidepressants: an analysis of data from The Health Improvement Network. J Clin Psychiatry. 72(7):979–985 Swanson SA, Hernandez-Diaz S, Palmsten K, Mogun H, Olfson M, Huybrechts K (2015) Methodological considerations in assessing the effectiveness of antidepressant medication continuation during pregnancy using administrative data. Pharmacoepidemiol Drug Saf 24(9):934–942 Yonkers KA, Blackwell KA, Glover J, Forray A (2014) Antidepressant use in pregnant and postpartum women. Annu Rev Clin Psychol 10:369–392 Zhao Y, Hebert MF, Venkataramanan R (2014) Basic obstetric pharmacology. Semin Perinatol 38(8):475–486 Yu T, Campbell S, Stockmann C, et al. Pregnancy-induced changes in the pharmacokinetics of caffeine and its metabolites. The Journal of Clinical Pharmacology. 2015:n/a-n/a. Ewing G, Tatarchuk Y, Appleby D, Schwartz N, Kim D (2015) Placental transfer of antidepressant medications: implications for postnatal adaptation syndrome. Clin Pharmacokinet 54(4):359–370 DeVane CL (1994) Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry. 55(Suppl):38–45 discussion 46-37 Sundell KA, Gissler M, Petzold M, Waern M (2011) Antidepressant utilization patterns and mortality in Swedish men and women aged 20–34 years. Eur J Clin Pharmacol 67(2):169–178 Zoega H, Kieler H, Norgaard M et al (2015) Use of SSRI and SNRI antidepressants during pregnancy: a population-based study from Denmark, Iceland. Norway and Sweden PloS one 10(12):e0144474 Giurgescu C, Engeland CG, Templin TN (2015) Symptoms of depression predict negative birth outcomes in African American women: a pilot study. J Midwifery Womens Health 60(5):570–577 Raisanen S, Lehto SM, Nielsen HS, Gissler M, Kramer MR, Heinonen S (2014) Risk factors for and perinatal outcomes of major depression during pregnancy: a population-based analysis during 2002–2010 in Finland. BMJ Open 4(11):e004883